InsiderTrades

Form 4 for BMRN BIOMARIN PHARMACEUTICAL INC

Accepted 2022-04-18 00:00:00 ET · period of report 2022-04-14 · accession 0001567619-22-008635 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-04-18 2022-04-14 BMRN BIENAIME JEAN JACQUES CEO, Dir M - OptEx $37.46 +10.0K 345.0K +3% +$374.6K
D 2022-04-18 2022-04-14 BMRN BIENAIME JEAN JACQUES CEO, Dir S - Sale+OE $83.66 -10.0K 335.0K -3% -$836.6K
D 2022-04-18 2022-04-14 BMRN BIENAIME JEAN JACQUES CEO, Dir M - OptEx $0.00 -10.0K 75.0K -12% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-04-14 M A 10,000 $37.46 344,983 D — — (F1) Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022. Mr. Bienaime's former spouse will receive approximately 70% of the net proceeds from the shares sold in this transaction pursuant to a marital separation agreement between her and Mr. Bienaime.
2 Common Common Stock 2022-04-14 S D 10,000 $83.66 334,983 D — — (F1) Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022. Mr. Bienaime's former spouse will receive approximately 70% of the net proceeds from the shares sold in this transaction pursuant to a marital separation agreement between her and Mr. Bienaime.
3 Derivative Stock Option (Right to buy Common Stock) 2022-04-14 M D 10,000 $0.00 75,000 D $37.46 · 2012-11-08 to 2022-05-07 10,000 Common Stock (F1) Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022. Mr. Bienaime's former spouse will receive approximately 70% of the net proceeds from the shares sold in this transaction pursuant to a marital separation agreement between her and Mr. Bienaime. (F2) Reflects the number of options outstanding after the transactions from this specific stock option grant.